Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?


Abundant evidence from large-scale clinical trials supports the importance of lowering low-density lipoprotein cholesterol (LDL-C) to decrease the risk of cardiovascular disease (CVD) events. The LDL-C targets in various guidelines remain important treatment goals but, even in trials where statin therapy achieves substantial reduction of LDL-C, a… (More)
DOI: 10.1007/s12325-009-0025-6


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics